Fig. 3.
IDH1R132H and IDH2R172K overexpression did not affect TMZ sensitivity. (A) Cells were treated with various doses of TMZ for 72 h. Viability was quantitated with MTT assay and expressed as mean percentage of untreated control cells (mean ± SEM, n =3). (B) Cells were treated with 400 μM of TMZ for different periods of time. Viability was quantitated with MTT assay and expressed as mean percentage of untreated control cells (mean ± SEM, n =3). (C) Clonogenic survival of cells after TMZ treatment was plotted on a logarithmic scale (mean ± SEM, n =3). *P < .05, **P < .01 compared with control, IDH1R132H or IDH2R172K cells.